V. Zherdev

Publications177
h-index6
Citations248
Highly Influential Citations5
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • A. Vasilyev
  • 49 Publications • 150 Citations
  • T. Gudasheva
  • 126 Publications • 413 Citations
  • V. S. Kuznetsov
  • 52 Publications • 82 Citations
  • S. Seredenin
  • 242 Publications • 1,128 Citations
  • Publications
  • Influence
Species differences in phenazeram kinetics and metabolism
TLDR
The results suggest that 3-OH- phenazepam might contribute to the overall pharmacological effects of the parent compound in those species in which it accumulates in significant amounts.
[Comparative pharmacokinetics of dihydroquercetin in rats upon peroral administration of a parent compound and liposomal flamen D].
The pharmacokinetics of dihydroquercetin (DHQ) in the forms of parent substance and a new liposomal formulation (Flamena D) have been studied in rats upon single peroral administration in a dose of…
[Bemetil pharmacokinetics in an experiment on rats].
TLDR
It was found that at intragastric administration the drug rapidly appeared in the systemic circulation, reached the maximal concentration in one hour; the character of bemetil elimination from the blood was biexponential at both routes of administration.
Identification of a novel endogenous memory facilitating cyclic dipeptide cyclo‐prolylglycine in rat brain
Regional and Subcellular Localization of Cycloprolylglycine in Rat Brain
HPLC analysis showed that endogenous cyclopeptide cycloprolylglycine exhibiting mnemotropic and anxiolytic properties is nonuniformly distributed between brain structures in rats: its contents in the…
The major metabolite of dipeptide piracetam analogue GVS-111 in rat brain and its similarity to endogenous neuropeptide cyclo-l-prolylglycine
TLDR
The metabolism of a new piracetam analogue, the dipeptide cognitive enhancer N-phenylacetyl-l-prolylglycine ethyl ester (GVS-111), was studied in vivo and could be considered as evidence that G VS-111 is prodrug which converts in the body to cyclo- Prolyl Glycine, and which is identical to the endogenous cyclopeptide that produces the nootropic activity.
Preclinical Pharmacokinetic and Pharmacodynamic Studies of Pharmaceutical Compositions of the Dipeptide Anxiolytic GB-115
TLDR
Four pharmaceutical compositions for oral use that contained the dipeptide anxiolytic GB-115 as the active ingredient underwent preclinical trials in male laboratory white rats and it was shown that compositions 2 and 4 had advantages according to the main pharmacokinetic characteristics reflecting the bioavailability ofGB-115.
Comparative Preclinical Pharmacokinetics and Bioavailability of Antidepressant GSB-106 Tablet Form
Pharmacokinetics and relative bioavailability of antidepressant GSB-106 (hexamethylendiamide bis-(N-monosuccinyl-L-seryl-L-lysine) were determined in rabbits after single oral administration of the…
The relationship between the content of the potential psychopharmacological agent cyclo-L-prolylglycine in the brain of experimental animals and its antihypoxic effect
HPLC-MS method development and validation for simultaneous quantitation of GZK-111 and CPG compounds in rat plasma
The technique of quantitative determination of GZK-111 and CPG compounds in rat blood plasma has been developed. The analysis was carried out using the combined method of high-performance liquid…
...
1
2
3
4
5
...